Loading...
EGFR-TKI原发性耐药的分子机制及其进展——附2例病例分析
Tyrosine kinase inhibitor (TKI) have been proved to be effective in the treatment of advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) sensitive mutation, which is superior to chemotherapy. However, there are still some patients with sensitive mutation...
Na minha lista:
| Udgivet i: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
中国肺癌杂志编辑部
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6348160/ https://ncbi.nlm.nih.gov/pubmed/30674394 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.01.10 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|